LEXX
HEALTHCARELexaria Bioscience Corp
$0.67-0.02 (-2.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LEXX Today?
No stock-specific AI insight has been generated for LEXX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.46$1.55
$0.67
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume155K
Avg Volume (10D)—
Shares Outstanding24.8M
LEXX News
20 articles- Lexaria Updates Progress on Human Study #7Yahoo Finance·May 5, 2026
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder CommunicationsYahoo Finance·May 1, 2026
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is ExtendedYahoo Finance·Apr 29, 2026
- Lexaria Launches New Study to Examine Next-Generation GLP-1 DrugsYahoo Finance·Apr 23, 2026
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry SalesYahoo Finance·Apr 21, 2026
- Lexaria's New Animal Study Aims to Expand Valuable Intellectual PropertyYahoo Finance·Apr 15, 2026
- Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash WiselyYahoo Finance·Apr 15, 2026
- Lexaria Applauds Eli Lilly's Foundayo(TM) Drug ApprovalYahoo Finance·Apr 7, 2026
- Lexaria to Begin New Human Clinical Study in GLP-1Yahoo Finance·Apr 1, 2026
- Lexaria's Robust Patent Portfolio Continues to GrowYahoo Finance·Mar 26, 2026
- Lexaria's Oral GLP-1 Drug Strategy Validated by IndustryYahoo Finance·Mar 24, 2026
- Lexaria Announces New R&D Plans for 2026Yahoo Finance·Mar 4, 2026
- LEXX: First Quarter ResultsYahoo Finance·Feb 10, 2026
- Lexaria Announces Positive Final Results From Human Pilot Study #5Yahoo Finance·Feb 5, 2026
- Lexaria Awarded Six Additional PatentsYahoo Finance·Jan 22, 2026
- Lexaria Releases Annual Letter from the CEOYahoo Finance·Jan 12, 2026
- Lexaria releases additional results from Phase 1b study GLP-1-H24-4Yahoo Finance·Dec 31, 2025
- Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4Yahoo Finance·Dec 30, 2025
- LEXX: DehydraTECH Formulation Reduces GLP-1 Agonist Side EffectsYahoo Finance·Dec 24, 2025
- Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4Yahoo Finance·Dec 23, 2025
All 20 articles loaded
Price Data
Open$0.70
Previous Close$0.69
Day High$0.72
Day Low$0.66
52 Week High$1.55
52 Week Low$0.46
52-Week Range
$0.46$1.55
$0.67
Fundamentals
Market Cap$17M
P/E Ratio—
EPS$-0.47
Dividend Yield—
Dividend / Share—
ROE-1.5%
Profit Margin—
Debt / Equity—
Trading
Volume155K
Avg Volume (10D)—
Shares Outstanding24.8M
About Lexaria Bioscience Corp
Lexaria Bioscience Corp. The company is headquartered in Kelowna, Canada.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—